flowable composite

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

flowable composite is one of 5 small molecule programs targeting X-linked hypophosphatemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

X-Linked HypophosphatemiaActive, not recruiting

X-Linked HypophosphatemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in X-Linked Hypophosphatemia

#DrugCompanyPhaseTrials

Rocaltrol

Alnylam Pharmaceuticals

Approved

2 2

CRYSVITA

Kyowa Kirin Co., Ltd.

Phase 2

6 3

KRN23

Kyowa Kirin Co., Ltd.

Phase 2

4 4

flowable composite

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 5

Salmon Calcitonin

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

X-linked hypophosphatemia1 trial

Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04872907·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for flowable composite. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — flowable composite compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for flowable composite. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

flowable composite

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

X-linked hypophosphatemia1 trial

References

Drug Info

Quick Facts

Related News